James Paul Lang - 02 Jan 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: Director
Signature: /s/ James R. Oehler, Attorney-in-Fact
Issuer symbol: HALO
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2026, 18:56:43 UTC
Previous filing: 05 Jan 2026
Next filing: 09 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lang James Paul	Director	12390 EL CAMINO REAL, SAN DIEGO	/s/ James R. Oehler, Attorney-in-Fact	06 Jan 2026	0001703090

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Restricted Stock Units	Award	$0	+889		$0.000000	889	02 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Option to Purchase Common Stock	Award	$0	+1,342		$0.000000	1,342	02 Jan 2026	Common Stock	1,342	$70.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2026 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
F2	Represents a stock options granted under the Issuer director compensation program. This grant will vest in full on the date of the Issuer 2026 annual meeting of stockholders.

Content

Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2026 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Represents a stock options granted under the Issuer director compensation program. This grant will vest in full on the date of the Issuer 2026 annual meeting of stockholders.